EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Dual glucagon‐like peptide ‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity

Rajna Golubic iD, Jane Kennet, Victoria Parker iD, Darren Robertson, Dan Luo, Lars Hansen, Lutz Jermutus iD, Phil Ambery iD, Maria Ryaboshapkina iD, Manasa Surakala, Rhianna C Laker, Michelle Venables und 3 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15579 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Rajna Golubic und 14 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Energy Intake, Weight Loss. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To establish which components of energy balance mediate the clinically significant weight loss demonstrated with use of cotadutide, a glucagon‐like peptide‐1 (GLP‐1)/glucagon receptor dual agonist, in early‐phase studies. Materials and Methods We conducted a phase 2a, single‐centre, randomized, placebo‐controlled trial in overweight and obese adults with type 2 diabetes. Following a 16‐day single‐blind placebo run‐in, participants were randomized 2:1 to double‐blind 42‐day subcutaneous treatment with cotadutide (100–300 μg daily) or placebo. The primary outcome was percentage weight change. Secondary outcomes included change in energy intake (EI) and energy expenditure (EE).

Results

A total of 12 participants (63%) in the cotadutide group and seven (78%) in the placebo group completed the study. The mean (90% confidence interval [CI]) weight change was −4.0% (−4.9%, −3.1%) and −1.4% (−2.7%, −0.1%) for the cotadutide and placebo groups, respectively ( p = 0.011). EI was lower with cotadutide versus placebo (−41.3% [−66.7, −15.9]; p = 0.011). Difference in EE (per kJ/kg lean body mass) for cotadutide versus placebo was 1.0% (90% CI −8.4, 10.4; p = 0.784), assessed by doubly labelled water, and −6.5% (90% CI −9.3, −3.7; p < 0.001), assessed by indirect calorimetry.

Conclusion

Weight loss with cotadutide is primarily driven by reduced EI, with relatively small compensatory changes in EE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityEnergy IntakeWeight LossEnergy MetabolismHumansMaleFemaleMiddle AgedDouble-Blind MethodAdultHypoglycemic AgentsReceptors, GlucagonGlucagon-Like Peptide 1Single-Blind MethodAgedTreatment OutcomePeptidesGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

clinical trialdrug developmentenergy regulationincretin physiologyweight control

Substanzen

cotadutideHypoglycemic AgentsReceptors, GlucagonGlucagon-Like Peptide 1PeptidesGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Oxford Centre for Diabetes Endocrinology and Metabolism, University of Oxford, Oxford, UK.
  • Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Statistics, Biometrics Oncology, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Late Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Rajna Golubic, Victoria Parker, Lutz Jermutus, Phil Ambery, Maria Ryaboshapkina, Mark Evans

Förderung

  • AstraZeneca

Zitieren

APA

Golubic, R., Kennet, J., Parker, V., Robertson, D., Luo, D., Hansen, L., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., Laker, R. C., Venables, M., Koulman, A., Park, A., & Evans, M. (2024). Dual glucagon‐like peptide ‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15579

Vancouver

Golubic R, Kennet J, Parker V, Robertson D, Luo D, Hansen L, et al. Dual glucagon‐like peptide ‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15579

BibTeX
@article{Golubic2024,
  author = {Golubic, Rajna and Kennet, Jane and Parker, Victoria and Robertson, Darren and Luo, Dan and Hansen, Lars and Jermutus, Lutz and Ambery, Phil and Ryaboshapkina, Maria and Surakala, Manasa and Laker, Rhianna C and Venables, Michelle and Koulman, Albert and Park, Adrian and Evans, Mark},
  title = {Dual glucagon‐like peptide ‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15579}
}
Kostenlos starten →